Kinetics of avibactam inhibition against class A, C, and D β-lactamases

Journal of Biological Chemistry

Volumn 288, Issue 39, 2013, Pages 27960-27971

  Ehmann, David E ^a   Jahić, Haris ^a   Ross, Philip L ^a   Gu, Rong Fang ^a   Hu, Jun ^a   Durand Réville, Thomas F ^a   Lahiri, Sushmita ^a   Thresher, Jason ^a   Livchak, Stephania ^a   Gao, Ning ^a   Palmer, Tiffany ^a   Walkup, Grant K ^a   Fisher, Stewart L ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACYL-ENZYMES; BROAD SPECTRUM; CLASS A; INHIBITION EFFICIENCY; LACTAMASES;

BIOCHEMISTRY; BIOLOGY;

ENZYME INHIBITION;

AVIBACTAM; BETA LACTAMASE; BETA LACTAMASE AMPC; BETA LACTAMASE CTX M 15; BETA LACTAMASE KPC 2; BETA LACTAMASE OXA 10; BETA LACTAMASE OXA 48; UNCLASSIFIED DRUG;

ACYLATION; ARTICLE; DEACYLATION; DRUG STRUCTURE; ENZYME INHIBITION; ENZYME STABILITY; HYDROLYSIS; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ANTIBIOTICS; DRUG DISCOVERY; ENZYME INHIBITORS; ENZYME KINETICS; MASS SPECTROMETRY (MS);

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASES; DRUG RESISTANCE, BACTERIAL; ENTEROBACTER CLOACAE; ENZYME INHIBITORS; ESCHERICHIA COLI; HYDROLYSIS; KINETICS; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; MICROBIAL SENSITIVITY TESTS; PLASMIDS; PSEUDOMONAS AERUGINOSA; TIME FACTORS;

EID: 84884764949     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M113.485979     Document Type: Article

References (40)

1. Shahid, M., Sobia, F., Singh, A., Malik, A., Khan, H. M., Jonas, D., and Hawkey, P. M. (2009) β-Lactams andβ-lactamase-inhibitors in current or potential clinical practice. A comprehensive update. Crit. Rev. Microbiol. 35, 81-108
2. Bebrone, C., Lassaux, P., Vercheval, L., Sohier, J. S., Jehaes, A., Sauvage, E., and Galleni, M. (2010) Current challenges in antimicrobial chemotherapy. Focus on β-lactamase inhibition. Drugs 70, 651-679
3. Drawz, S. M., and Bonomo, R. A. (2010) Three decades of β-lactamase inhibitors. Clin. Microbiol. Rev. 23, 160-201
4. Bush, K., and Fisher, J. F. (2011) Epidemiological expansion, structural studies, and clinical challenges of new β-lactamases from Gram-negative bacteria. Annu. Rev. Microbiol. 65, 455-478
5. Bush, K., and Jacoby, G. A. (2010) Updated functional classification of β-lactamases. Antimicrob. Agents Chemother. 54, 969-976
6. Fink, A. L., and Page, M. I. (2012) in β-lactamases (Frere, J., ed.) p. 161, Nova Science Publishers, New York
7. Bush, K., and Macielag, M. J. (2010) New β-lactam antibiotics and β-lactamase inhibitors. Expert Opin. Ther. Pat. 20, 1277-1293
8. Shlaes, D. M. (2013) New β-lactam-β-lactamase inhibitor combinations in clinical development. Ann. N.Y. Acad. Sci. 1277, 105-114
9. Bush, K. (2012) Improving known classes of antibiotics. An optimistic approach for the future. Curr. Opin. Pharmacol. 12, 527-534
10. Coleman, K. (2011) Diazabicyclooctanes (DBOs). A potent new class of non-β-lactamβ-lactamase inhibitors. Curr. Opin. Microbiol. 14, 550-555
11. Zhanel, G. G., Lawson, C. D., Adam, H., Schweizer, F., Zelenitsky, S., Lagacé-Wiens, P. R., Denisuik, A., Rubinstein, E., Gin, A. S., Hoban, D. J., Lynch, J. P., 3rd, and Karlowsky, J. A. (2013) Ceftazidime-avibactam. A novel cephalosporin/β-lactamase inhibitor combination. Drugs 73, 159-177
12. Aktaş, Z., Kayacan, C., and Oncul, O. (2012) In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. Int. J. Antimicrob. Agents 39, 86-89
13. Levasseur, P., Girard, A. M., Claudon, M., Goossens, H., Black, M. T., Coleman, K., and Miossec, C. (2012) In vitro antibacterial activity of the ceftazidime-avibactam (NXL104) combination against Pseudomonas aeruginosa clinical isolates. Antimicrob. Agents Chemother. 56, 1606-1608
14. Dubreuil, L. J., Mahieux, S., Neut, C., Miossec, C., and Pace, J. (2012) Anti-anaerobic activity of a new β-lactamase inhibitor NXL104 in combination with β-lactams and metronidazole. Int. J. Antimicrob. Agents 39, 500-504
15. Bonnefoy, A., Dupuis-Hamelin, C., Steier, V., Delachaume, C., Seys, C., Stachyra, T., Fairley, M., Guitton, M., and Lampilas, M. (2004) In vitro activity of AVE1330A, an innovative broad-spectrum non-β-lactam β-lactamase inhibitor. J. Antimicrob. Chemother. 54, 410-417
16. Stachyra, T., Péchereau, M. C., Bruneau, J. M., Claudon, M., Frère, J. M., Miossec, C., Coleman, K., and Black, M. T. (2010) Mechanistic studies of the inactivation of TEM-1 and P99 by NXL104, a novel non-β-lactam β-lactamase inhibitor. Antimicrob. Agents Chemother. 54, 5132-5138
17. Xu, H., Hazra, S., and Blanchard, J. S. (2012) NXL104 irreversibly inhibits the β-lactamase from Mycobacterium tuberculosis. Biochemistry 51, 4551-4557
18. Ehmann, D. E., Jahić, H., Ross, P. L., Gu, R. F., Hu, J., Kern, G., Walkup, G. K., and Fisher, S. L. (2012) Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc. Natl. Acad. Sci. U.S.A. 109, 11663-11668
19. Stachyra, T., Levasseur, P., Péchereau, M. C., Girard, A. M., Claudon, M., Miossec, C., and Black, M. T. (2009) In vitro activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J. Antimicrob. Chemother. 64, 326-329
20. Bush, K. (2013) Proliferation and significance of clinically relevant β-lactamases. Ann. N.Y. Acad. Sci. 1277, 84-90
21. Patel, G., and Bonomo, R. A. (2013) "Stormy waters ahead." Global emergence of carbapenemases. Front. Microbiol. 4, 48
22. Poirel, L., Naas, T., and Nordmann, P. (2010) Diversity, epidemiology, and genetics of class D β-lactamases. Antimicrob. Agents Chemother. 54, 24-38
23. Gupta, N., Limbago, B. M., Patel, J. B., and Kallen, A. J. (2011) Carbapenem-resistant Enterobacteriaceae. Epidemiology and prevention. Clin. Infect. Dis. 53, 60-67
24. Lahiri, S. D., Mangani, S., Durand-Reville, T., Benvenuti, M., De Luca, F., Sanyal, G., and Docquier, J. D. (2013) Structural insight into potent broadspectrum inhibition with reversible recyclization mechanism. Avibactam in complex with CTX-M-15 and Pseudomonas aeruginosa AmpC β-lactamases. Antimicrob. Agents Chemother. 57, 2496-2505
25. Morrison, J. F., and Walsh, C. T. (1988) The behavior and significance of slow-binding enzyme inhibitors. Adv. Enzymol. Relat. Areas Mol. Biol. 61, 201-301
26. Miles, R. W., Tyler, P. C., Furneaux, R. H., Bagdassarian, C. K., and Schramm, V. L. (1998) One-third-the-sites transition-state inhibitors for purine nucleoside phosphorylase. Biochemistry 37, 8615-8621
27. Golemi, D., Maveyraud, L., Vakulenko, S., Samama, J. P., and Mobashery, S. (2001) Critical involvement of a carbamylated lysine in catalytic function of classDβ-lactamases. Proc. Natl. Acad. Sci. U.S.A. 98, 14280-14285
28. Breitmaier, E. (1999) Structure Elucidation byNMRin Organic Chemistry, pp. 49-52, John Wiley and Sons, New York
29. Papp-Wallace, K. M., Bethel, C. R., Distler, A. M., Kasuboski, C., Taracila, M., and Bonomo, R. A. (2010) Inhibitor resistance in the KPC-2 β-lactamase, a preeminent property of this class A β-lactamase. Antimicrob. Agents Chemother. 54, 890-897
30. Papp-Wallace, K. M., Taracila, M. A., Smith, K. M., Xu, Y., and Bonomo, R. A. (2012) Understanding the molecular determinants of substrate and inhibitor specificities in the carbapenemase KPC-2. Exploring the roles of Arg-220 and Glu-276. Antimicrob. Agents Chemother. 56, 4428-4438
31. Livermore, D. M., Mushtaq, S., Warner, M., Zhang, J., Maharjan, S., Doumith, M., and Woodford, N. (2011) Activities of NXL104 combinations with ceftazidime and aztreonam against carbapenemase-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 55, 390-394
32. Mushtaq, S., Warner, M., and Livermore, D. M. (2010) In vitro activity of Ceftazidime NXL104 against Pseudomonas aeruginosa and other nonfermenters. J. Antimicrob. Chemother. 65, 2376-2381
33. Livermore, D. M., Mushtaq, S., Warner, M., Miossec, C., and Woodford, N. (2008) NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum β-lactamases and carbapenemases. J. Antimicrob. Chemother. 62, 1053-1056
34. Walkty, A., DeCorby, M., Lagacé-Wiens, P. R., Karlowsky, J. A., Hoban, D. J., and Zhanel, G. G. (2011) In vitro activity of ceftazidime combined with NXL104 versus Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals (CANWARD 2009 study). Antimicrob. Agents Chemother. 55, 2992-2994
35. Drawz, S. M., Taracila, M., Caselli, E., Prati, F., and Bonomo, R. A. (2011) Exploring sequence requirements for C/C carboxylate recognition in the Pseudomonas aeruginosa cephalosporinase. Insights into plasticity of the AmpC β-lactamase. Protein Sci. 20, 941-958
36. Kovach, M. E., Elzer, P. H., Hill, D. S., Robertson, G. T., Farris, M. A., Roop, R. M., 2nd, and Peterson, K. M. (1995) Four new derivatives of the broadhost-range cloning vector pBBR1MCS, carrying different antibiotic- resistance cassettes. Gene 166, 175-176
37. Pratt, R. (2012) inβ-Lactamases (Frere, J., Ed.) Nova Science Publishers, p. 259, New York
38. Bethel, C. R., Taracila, M., Shyr, T., Thomson, J. M., Distler, A. M., Hujer, K. M., Hujer, A. M., Endimiani, A., Papp-Wallace, K., Bonnet, R., and Bonomo, R. A. (2011) Exploring the inhibition of CTX-M-9 by β-lactamase inhibitors and carbapenems. Antimicrob. Agents Chemother. 55, 3465-3475
39. De Luca, F., Benvenuti, M., Carboni, F., Pozzi, C., Rossolini, G. M., Mangani, S., and Docquier, J. D. (2011) Evolution to carbapenem-hydrolyzing activity in noncarbapenemase class D β-lactamase OXA-10 by rational protein design. Proc. Natl. Acad. Sci. U.S.A. 108, 18424-18429
40. Jencks, W. P. (1997) From chemistry to biochemistry to catalysis to movement. Annu. Rev. Biochem. 66, 1-18